<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> is widely used as a second-line antimicrobial for <z:hpo ids='HP_0001061'>acne</z:hpo> vulgaris </plain></SENT>
<SENT sid="1" pm="."><plain>Some patients require doses of up to 200 mg daily to control their <z:hpo ids='HP_0001061'>acne</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To assess the long-term safety of <z:chebi fb="1" ids="50694">minocycline</z:chebi> when used at higher doses, 700 patients treated with <z:chebi fb="1" ids="50694">minocycline</z:chebi> at doses of 100 mg daily, 100/200 mg on alternate days and 200 mg daily, were recruited </plain></SENT>
<SENT sid="3" pm="."><plain>The mean duration of treatment was 10.5 months </plain></SENT>
<SENT sid="4" pm="."><plain>Side-effects were monitored and full blood count, blood <z:chebi fb="20" ids="16199">urea</z:chebi>, electrolytes and liver function tests were carried out on 200 of the 700 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Side-effects were recorded in 13.6%, and included vestibular disturbance, <z:e sem="disease" ids="C0006840" disease_type="Disease or Syndrome" abbrv="">candida infection</z:e>, gastrointestinal disturbance, cutaneous symptoms (<z:hpo ids='HP_0001000'>pigmentation</z:hpo>, <z:hpo ids='HP_0000989'>pruritus</z:hpo>, <z:e sem="disease" ids="C0162830" disease_type="Disease or Syndrome" abbrv="">photosensitive rash</z:e> and <z:hpo ids='HP_0001025'>urticaria</z:hpo>) and benign intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001000'>Pigmentation</z:hpo> was the only side-effect found to be significantly increased in patients taking higher doses of <z:chebi fb="1" ids="50694">minocycline</z:chebi>, as compared with lower doses (P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:hpo ids='HP_0001000'>pigmentation</z:hpo> had taken a total cumulative dose of over 70 g </plain></SENT>
<SENT sid="8" pm="."><plain>No significant abnormalities were found in any of the haematological and biochemical profiles </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that <z:chebi fb="1" ids="50694">minocycline</z:chebi>, at doses of up to 200 mg/day, is safe, long-term, for <z:hpo ids='HP_0001061'>acne</z:hpo>, when such doses are clinically necessary </plain></SENT>
</text></document>